Answers are grounded in this paper and cite their sources.
Let me start by summarizing what we (think we) know and don’t know that pertains to this issue. In the mid-1960s (when I was a fellow), the conventional wisdom was that the complications of diabetes were unrelated to glycemic control; they were genetically determined. Therefore, the clinical goal was simply to keep diabetic patients asymptomatic. Fifteen years later, animal and some retrospective human studies convinced some (1) that near euglycemia would have a beneficial effect on diabetes complications. Controversy surrounding this issue raged until the results of the Diabetes Control and Complications Trial (DCCT) were published (2). Some controversy remained regarding extending the DCCT results to type 2 diabetes (3,4), but with the publication of the U.K. Prospective Diabetes Study (UKPDS) (5,6), the beneficial effects of near euglycemia on microvascular complications were irrefutably established for both type 1 and type 2 diabetic patients. In the past decade, five studies evaluating >2,000 patients with both type 1 (7–9) and type 2 (10,11) diabetes over 6–9 years have demonstrated that development or progression of retinopathy and microalbuminuria were minimal or absent if A1C levels were maintained below 7%, increased only slightly if A1C levels were between 7 and 8%, but increased markedly at values exceeding 8%. It is important to distinguish between the micro- and macrovascular complications when considering the impact of near euglycemia on diabetes complications because they are often lumped together in arguments for tight control.
No takes yet. Share an insight, caveat, or question.
Mayer B. Davidson (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: